scholarly journals The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient‐Reported Outcomes in Systemic Lupus Erythematosus (SLE)

2021 ◽  
Author(s):  
Patricia Katz ◽  
Sofia Pedro ◽  
Laura Trupin ◽  
Edward Yelin ◽  
Kaleb Michaud
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Lupus Erythematosus ◽  
Patient Reported Outcomes ◽  
Chronic Obstructive ◽  
Systemic Lupus ◽  
Obstructive Pulmonary Disease ◽  
Patient Reported ◽  
The Impact

scholarly journals A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

2016 ◽  
Vol 2 (2) ◽  
pp. 00101-2015 ◽  
Author(s):  
Tara Rheault ◽  
Sanjeev Khindri ◽  
Mitra Vahdati-Bolouri ◽  
Alison Church ◽  
William A. Fahy
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Patient Reported Outcomes ◽  
Chronic Obstructive ◽  
Open Label ◽  
Obstructive Pulmonary Disease ◽  
Once Daily ◽  
Inferior Margin ◽  
Link Type ◽  
Patient Reported

This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease.This was a 12-week, multicentre, randomised, open-label, parallel-group study (Clinicaltrials.gov: NCT02236611). Patients were randomised 1:1 to umeclidinium 62.5 µg or glycopyrronium 50 µg administered via Ellipta or Breezhaler dry powder inhaler, respectively. The primary endpoint was trough forced expiratory volume in 1 s (FEV1) at day 85 in the per-protocol population. Other endpoints included: weighted mean FEV1 over 0–24 h and patient-reported outcomes (transition dyspnoea index score and St George's Respiratory Questionnaire total score). Adverse events were also assessed.A total of 1037 patients were randomised to treatment. Umeclidinium was non-inferior (margin: −50 mL) to glycopyrronium (trough FEV1 at day 85 treatment difference: 24 mL, 95% confidence intervals: −5–54). Improvements in other endpoints were similar between treatments. Adverse event incidences were similar for umeclidinium (37%) and glycopyrronium (36%).Once-daily umeclidinium was non-inferior to once-daily glycopyrronium in patients with chronic obstructive pulmonary disease in trough FEV1 at day 85. Patient-reported outcomes and safety profiles were similar for both treatments.

scholarly journals Inhalation glucocorticosteroids in the treatment of chronic obstructive pulmonary disease

2020 ◽  
Vol 30 (3) ◽  
pp. 330-343
Author(s):  
S. N. Avdeev ◽  
Z. R. Aisanov ◽  
V. V. Arkhipov ◽  
A. S. Belevskiy ◽  
I. V. Leshchenko ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive Lung Disease ◽  
Clinical Excellence ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Exacerbations ◽  
Patient Reported ◽  
The Impact

The main objectives of chronic obstructive pulmonary disease (COPD) therapy are to reduce the severity of symptoms and the risk of exacerbations. The article discusses the role of local and systemic inflammation in the pathogenesis of COPD as well as various mechanisms of pharmacological influence on it. Approaches to prescribing basic therapy for patients with COPD, recommended by various national and global guidelines (clinical recommendations of the Russian respiratory society, criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), guidelines of the National Institute for Health and Clinical Excellence (NICE)), as well as recommendations on the therapy frequency review are considered. Currently, so-called triple combinations – fixed combinations of double bronchodilators with inhaled glucocorticosteroids – are being developed and registered in the world, and their place and significance in the treatment of COPD raise many discussions. The paper discusses the role of fixed triple combinations in reducing the incidence of COPD exacerbations, the impact on functional and patient-reported outcomes, and provides recommendations for the use of triple combinations in patients with COPD, taking into account the benefit/risk ratio.

Sign in / Sign up

Export Citation Format

Share Document